Analyst Price Targets — BVS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 9, 2026 12:55 pm | — | Barrington | $13.00 | $8.51 | TheFly | Bioventus initiated with an Outperform at Barrington |
| May 7, 2025 1:16 pm | Chase Knickerbocker | Craig-Hallum | $15.00 | $6.20 | TheFly | Bioventus price target lowered to $15 from $17 at Craig-Hallum |
| October 1, 2024 1:38 pm | Caitlin Cronin | Canaccord Genuity | $12.00 | $11.79 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on Bioventus Inc (BVS) |
| August 7, 2024 9:05 am | Chase Knickerbocker | Craig-Hallum | $12.00 | $8.25 | TheFly | Bioventus price target raised to $12 from $9 at Craig-Hallum |
| May 7, 2024 1:38 pm | William Plovanic | Canaccord Genuity | $8.00 | $5.12 | StreetInsider | Bioventus Inc (BVS) PT Raised to $8 at Canaccord Genuity |
| March 13, 2024 8:42 am | Alex Nowak | Craig-Hallum | $9.00 | $5.29 | StreetInsider | Bioventus Inc (BVS) PT Raised to $9 at Craig-Hallum |
| November 30, 2022 8:31 am | — | Goldman Sachs | $2.50 | $1.91 | Benzinga | Goldman Sachs Maintains Neutral on Bioventus, Lowers Price Target to $2.5 |
Latest News for BVS
Bioventus (BVS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Check-Cap (NASDAQ: MBAI - Get Free Report) and Bioventus (NASDAQ: BVS - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Insider and Institutional Ownership 1.1% of Check-Cap shares are
Biosig Technologies (NASDAQ: STEX - Get Free Report) and Bioventus (NASDAQ: BVS - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Volatility and Risk Biosig Technologies has a beta
Bioventus (NASDAQ: BVS) executives told investors the company closed 2025 with what leadership described as a "solid quarter" and a "pivotal year," highlighting stronger organic growth, higher profitability, and record quarterly operating cash flow while laying out a 2026 plan to step up investment in several growth initiatives. Fourth-quarter performance and mix For the fourth quarter,
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BVS.
U.S. House Trading
No House trades found for BVS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.